74 related articles for article (PubMed ID: 21345112)
1. More on crizotinib.
Orenstein JM
N Engl J Med; 2011 Feb; 364(8):777; author reply 778-9. PubMed ID: 21345112
[No Abstract] [Full Text] [Related]
2. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
[TBL] [Abstract][Full Text] [Related]
3. Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatory myofibroblastic tumor with crizotinib.
Kiratli H; Uzun S; Varan A; Akyüz C; Orhan D
J AAPOS; 2016 Jun; 20(3):260-3. PubMed ID: 27312965
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib--latest champion in the cancer wars?
Hallberg B; Palmer RH
N Engl J Med; 2010 Oct; 363(18):1760-2. PubMed ID: 20979477
[No Abstract] [Full Text] [Related]
5. More on crizotinib.
Chihara D; Suzuki R
N Engl J Med; 2011 Feb; 364(8):776-7; author reply 778. PubMed ID: 21345113
[No Abstract] [Full Text] [Related]
6. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
[TBL] [Abstract][Full Text] [Related]
7. More on crizotinib.
Shen L; Ji HF
N Engl J Med; 2011 Feb; 364(8):777-8. PubMed ID: 21345111
[No Abstract] [Full Text] [Related]
8. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib in anaplastic large-cell lymphoma.
Gambacorti-Passerini C; Messa C; Pogliani EM
N Engl J Med; 2011 Feb; 364(8):775-6. PubMed ID: 21345110
[No Abstract] [Full Text] [Related]
10. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
11. [Updates on inflammatory myofibroblastic tumor of head and neck region].
He CY; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):712-4. PubMed ID: 24433742
[No Abstract] [Full Text] [Related]
12. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
Giroux Leprieur E; Wislez M
Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
[No Abstract] [Full Text] [Related]
13. [Inflammatory myofibroblastic tumor].
Leuschner I
Pathologe; 2010 Mar; 31(2):106-8. PubMed ID: 20063099
[TBL] [Abstract][Full Text] [Related]
14. Complete Response of Anaplastic Lymphoma Kinase-Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib.
Thanarajasingam G; Edell ES; Markovic SM
Mayo Clin Proc; 2016 Sep; 91(9):1319-20. PubMed ID: 27594191
[No Abstract] [Full Text] [Related]
15. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Liu Q; Kan Y; Zhao Y; He H; Kong L
Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
[TBL] [Abstract][Full Text] [Related]
16. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
[No Abstract] [Full Text] [Related]
17. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
Costa DB; Kobayashi S
J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
[No Abstract] [Full Text] [Related]
18. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
[No Abstract] [Full Text] [Related]
19. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
Browning ET; Weickhardt AJ; Camidge DR
J Thorac Oncol; 2013 Mar; 8(3):e21. PubMed ID: 23407562
[No Abstract] [Full Text] [Related]
20. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
Gambacorti Passerini C; Farina F; Stasia A; Redaelli S; Ceccon M; Mologni L; Messa C; Guerra L; Giudici G; Sala E; Mussolin L; Deeren D; King MH; Steurer M; Ordemann R; Cohen AM; Grube M; Bernard L; Chiriano G; Antolini L; Piazza R
J Natl Cancer Inst; 2014 Feb; 106(2):djt378. PubMed ID: 24491302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
